The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Karpenko O.A.

Alekseev Psychiatric Clinical Hospital No. 1

Compliance and insight as factors of recovery in patients with schizophrenia spectrum disorders

Authors:

Karpenko O.A.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(1‑2): 41‑48

DOI: 10.17116/jnevro202212201241

Read: 3234 times

Download PDF (RU)
Contact the author
Table of contents

COMPLIANCE AND INSIGHT AS FACTORS OF RECOVERY IN PATIENTS WITH SCHIZOPHRENIA SPECTRUM DISORDERS
COMPLIANCE AND INSIGHT AS FACTORS OF RECOVERY IN PATIENTS WITH SCHIZOPHRENIA SPECTRUM DISORDERS

To cite this article:

Karpenko OA. Compliance and insight as factors of recovery in patients with schizophrenia spectrum disorders. S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(1‑2):41‑48. (In Russ.)
https://doi.org/10.17116/jnevro202212201241

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски (S.S. Korsakov Journal of Neurology and Psychiatry (special issues))
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Analysis of cognitive status in patients with different noso­logies and clinical variants of very late mani­festing schi­zophreniform psychosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):88-93
The role of immuno-inflammatory factors in the deve­lopment of nega­tive symptoms in schi­zophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):42-48
A role of transcription factors in pathogenic processes asso­ciated with schi­zophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):49-54
Meta­bolic syndrome and anti­psychotic therapy of schi­zophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):165-170
Neuronal models based on olfa­ctory epithelial cells in the study of the pathogenesis of mental diso­rders. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12):20-25
The asso­ciation of NOS1AP gene poly­morphisms with the dura­tion of the QT inte­rval in patients with schi­zophrenia receiving anti­psychotic therapy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):98-104
PANSS six-factor model. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):28-34
Clinical and immu­nological rela­tionships in patients with early schi­zophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):35-42
Clinical and psychopathological features of treatment-resistant schi­zophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):43-50
Obje­ctive Moni­toring of Compliance with Compression Treatment in Patients with Chro­nic Venous Disease is Better than Self-Reported Using Patient’s Diary. Journal of Venous Diso­rders. 2025;(2):113-119
Abstract:

The goal of the up-to-date treatment of patients with schizophrenia spectrum disorders is recovery, including personal recovery. This goal is a part of the patient-centered approach. This review examines factors that may influence recovery achievement. Compliance plays a key role in relapse prevention. Its formation, in turn, depends on patients’ participation in the treatment process, level of insight and patients’ ability and willingness to play an active role in the treatment and apply self-management. All of the mentioned above should be taken into account while implementing patient-centered approach. This dictates the need to develop clear evaluation criteria of recovery factors in medical care of patients with schizophrenia spectrum disorders.

Keywords:

compliance
insight
recovery
schizophrenia
person-centered approach

Authors:

Karpenko O.A.

Alekseev Psychiatric Clinical Hospital No. 1

Received:

12.11.2021

Accepted:

01.12.2021

Close metadata

References:

  1. Gurovich IYa, Lyubov EB, Storozhakova YaA. The concept of recovery in schizophrenia. Social and Clinical Psychiatry. 2008;(2):7-14. (In Russ.).
  2. Mueser KT, Deavers F, Penn DL, Cassisi JE. Psychosocial treatments for schizophrenia. Annu Rev Clin Psychol. 2013;9:465-497.  https://doi.org/10.1146/annurev-clinpsy-050212-185620
  3. Ahmed AO, Marino BA, Rosenthal E, et al. Recovery in Schizophrenia: What Consumers Know and Do Not Know. Psychiatr Clin North Am. 2016;39(2):313-330.  https://doi.org/10.1016/j.psc.2016.01.009
  4. Lean M, Fornells-Ambrojo M, Milton A, Lloyd-Evans B, Harrison-Stewart B, Yesufu-Udechuku A, Kendall T, Johnson S. Self-management interventions for people with severe mental illness: systematic review and meta-analysis. The British Journal of Psychiatry. 2019;214(5):260-268.  https://doi.org/10.1192/bjp.2019.54
  5. Taylor M, Jauhar S. Are we getting any better at staying better? The long view on relapse and recovery in first episode nonaffective psychosis and schizophrenia. Ther Adv Psychopharmacol. 2019;9:2045125319870033. https://doi.org/10.1177/2045125319870033
  6. Leamy M, Bird V, Le Boutillier C, Williams J, Slade M. Conceptual framework for personal recovery in mental health: systematic review and narrative synthesis. Br J Psychiatry. 2011;199(6):445-452.  https://doi.org/10.1192/bjp.bp.110.083733
  7. van Weeghel J, van Zelst C, Boertien D, Hasson-Ohayon I. Conceptualizations, assessments, and implications of personal recovery in mental illness: A scoping review of systematic reviews and meta-analyses. Psychiatr Rehabil J. 2019;42(2):169-181.  https://doi.org//10.1037/prj0000356
  8. Birchwood M, Todd P, Jackson C: Early intervention in psychosis: the critical period hypothesis. Br J Psychiatry Suppl. 1998;33:53-59. 
  9. Mayoral-van Son J, de la Foz VO, Martinez-Garcia O, Moreno T, Parrilla-Escobar M, Valdizan EM, Crespo-Facorro B. Clinical outcome after antipsychotic treatment discontinuation in functionally recovered first-episode nonaffective psychosis individuals. J Clin Psychiatry. 2016;77(4):492-500.  https://doi.org/10.4088/JCP.14m09540
  10. Masand PS, Roca M, Turner MS, Kane JM. Partial adherence to antipsychotic medication impacts the course of illness in patients with schizophrenia: a review. Prim Care Companion J Clin Psychiatry. 2009;11:147-154.  https://doi.org/10.4088/PCC.08r00612
  11. Leucht S, Tardy M, Komossa K, et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet. 2012;379(9831):2063-2071. https://doi.org/10.1016/S0140-6736(12)60239-6
  12. Olivares JM, Sermon J, Hemels M, Schreiner A. Definitions and drivers of relapse in patients with schizophrenia: a systematic literature review. Ann Gen Psychiatry. 2013;12(1):32.  https://doi.org/10.1186/1744-859X-12-32
  13. Kane JM. Treatment strategies to prevent relapse and encourage remission. J Clin Psychiatry. 2007;68(suppl 1):27-30. 
  14. Lieberman J, Jody D, Geisler S, et al. Time course and biologic correlates of treatment response in first-episode schizophrenia. Arch Gen Psychiatry. 1993;50:369-376. 
  15. Wiersma D, Nienhuis FJ, Slooff CJ, Giel R. Natural course of schizophrenic disorders: a 15-year follow-up of a Dutch incidence cohort. Schizophr Bull. 1998;24:75-85. 
  16. Andreasen NC, Liu D, Ziebell S, et al. Relapse duration, treatment intensity, and brain tissue loss in schizophrenia: a prospective longitudinal MRI study. Am J Psychiatry. 2013;170:609-615.  https://doi.org/10.1176/appi.ajp.2013.12050674
  17. Hong J, Windmeijer F, Novick D, et al. The cost of relapse in patients with schizophrenia in the European SOHO (Schizophrenia Outpatient Health Outcomes) study. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33:835-841.  https://doi.org/10.1016/j.pnpbp.2009.03.034
  18. Almond S, Knapp M, Francois C, Toumi M, Brugha T. Relapse in schizophrenia: costs, clinical outcomes and quality of life. British Journal of Psychiatry. 2004;184(4):346-351.  https://doi.org/10.1192/bjp.184.4.346
  19. Neznanov NG, Shmukler AB, Kostyuk GP, Sofronov AG. The first psychotic episode: epidemiological aspects of care provision. Social and Clinical Psychiatry. 2018;28(3):5-11. (In Russ.). https://doi.org/10.24412/FfsMecIxKWo
  20. McGorry PD. Psychoeducation in first-episode psychosis: a therapeutic process. Psychiatry. 1995;58(4):313-328.  https://doi.org/10.1080/00332747.1995.11024736
  21. Lieberman JA, Fenton WS. Delayed detection of psychosis: causes, consequences, and effect on public health (editorial). Am J Psychiatry. 2000;157:1727-1730.
  22. Limankin OV, Trushchelev SA. Psychosocial rehabilitation of patients with mental and behavioral disorders. Rossiiskii Psikhiatricheskii Zhurnal [Russian Journal of Psychiatry]. 2019;6:4-15. (In Russ.). https://doi.org/10.24411/1560-957X-2019-11949
  23. Katschnig H, Sint P. Late ‘Early Intervention in Psychosis’: A Family School for Learning How to Live with Schizophrenia. Consortium Psychiatricum. 2021;2(3):3-16.  https://doi.org/10.17816/CP99
  24. Robinson D, Woerner MG, Alvir JM, Bilder R, Goldman R, Geisler S, Koreen A, Sheitman B, Chakos M, Mayerhoff D, Lieberman JA. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry. 1999;56:241.  https://doi.org/10.1001/archpsyc.56.3.241
  25. Zipursky RB, Menezes NM, Streiner DL. Risk of symptom recurrence with medication discontinuation in first-episode psychosis: a systematic review. Schizophr Res. 2014;152:408-414.  https://doi.org/10.1016/j.schres.2013.08.001
  26. Winton-Brown TT, Elanjithara T, Power P, Coentre R, Blanco-Polaina P, McGuire P. Five‐fold increased risk of relapse following breaks in antipsychotic treatment of first episode psychosis. Schizophr Res. 2017;179:50‐56.  https://doi.org/10.1016/j.schres.2016.09.029
  27. Alvarez-Jimenez M, O’Donoghue B, Thompson A, Gleeson JF, Bendall S, Gonzalez-Blanch C, Killackey E, Wunderink L, McGorry PD. Beyond Clinical Remission in First Episode Psychosis: Thoughts on Antipsychotic Maintenance vs. Guided Discontinuation in the Functional Recovery Era. CNS Drugs. 2016;30(5):357-368.  https://doi.org/10.1007/s40263-016-0331-x
  28. Vita A, De Peri L, Deste G, Barlati S, Sacchetti E. The effect of antipsychotic treatment on cortical gray matter changes in schizophrenia: does the class matter? A meta-analysis and meta-regression of longitudinal magnetic resonance imaging studies. Biol Psychiatry. 2015;78:403-412.  https://doi.org/10.1016/j.biopsych.2015.02.008
  29. Murray RM, Quattrone D, Natesan S, van Os J, Nordentoft M, Howes O, Di Forti M, Taylor D. Should psychiatrists be more cautious about the long-term prophylactic use of antipsychotics? British Journal of Psychiatry. 2016;209(5):361-365.  https://doi.org/10.1192/bjp.bp.116.182683
  30. Begemann MJH, Thompson IA, Veling W, et al. To continue or not to continue? Antipsychotic medication maintenance versus dose-reduction/discontinuation in first episode psychosis: HAMLETT, a pragmatic multicenter single-blind randomized controlled trial. Trials. 2020;21(1):147.  https://doi.org/10.1186/s13063-019-3822-5
  31. Zipursky RB, Odejayi G, Agid O, Remington G. You say «schizophrenia» and I say «psychosis»: Just tell me when I can come off this medication. Schizophr Res. 2020;225:39-46.  https://doi.org/10.1016/j.schres.2020.02.009
  32. Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. Journal of Clinical Psychiatry. 2002;63(10):892‐909.  https://doi.org/10.4088/jcp.v63n1007
  33. Pelayo-Terán JM, Gajardo Galán VG, de la Ortiz-García de la Foz V, et al. Rates and predictors of relapse in first-episode non-affective psychosis: a 3-year longitudinal study in a specialized intervention program (PAFIP). Eur Arch Psychiatry Clin Neurosci. 2017;267:315-323.  https://doi.org/10.1007/s00406-016-0740-3
  34. Alvarez-Jimenez M, Priede A, Hetrick SE, Bendall S, Killackey E, Parker AG, McGorry PD, Gleeson JF. Risk factors for relapse following treatment for first episode psychosis: a systematic review and meta-analysis of longitudinal studies. Schizophr Res. 2012;139:116-128.  https://doi.org/10.1016/j.schres.2012.05.007
  35. Coldham EL, Addington J, Addington D. Medication adherence of individuals with a first episode of psychosis. Acta Psychiatr Scand. 2002;106:286-290. 
  36. Addington DE, Patten SB, McKenzie E, Addington J. Relationship between relapse and hospitalization in first-episode psychosis. Psychiatr Serv. 2013;64:796-799.  https://doi.org/10.1176/appi.ps.201200440
  37. Klingberg S, Schneider S, Wittorf A, Buchkremer G, Wiedemann G. Collaboration in outpatient antipsychotic drug treatment: analysis of potentially influencing factors. Psychiatry Res. 2008;30;161(2):225-234.  https://doi.org/10.1016/j.psychres.2007.07.027
  38. Robinson DG, Woerner MG, Alvir JM, Bilder RM, Hinrichsen GA, Lieberman JA. Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder. Schizophrenia Research. 2002;57(2-3):209-219.  https://doi.org/10.1016/S0920-9964(01)00312-7
  39. Rabinovitch M, Béchard-Evans L, Schmitz N, Joober R, Malla A. Early predictors of nonadherence to antipsychotic therapy in first-episode psychosis. Can J Psychiatry. 2009;54(1):28-35.  https://doi.org/10.1177/070674370905400106
  40. Lam YWF, Velligan DI, DiCocco M, Ereshefsky L, Maples N, Castillo D, Archuletta D, Korell S, Miller AL. Comparative assessment of antipsychotic adherence by concentration monitoring, pill count and self-report. Schizophr Res. 2003;60:313.  https://doi.org/10.1016/S0920-9964(03)80256-6
  41. Guo X, Zhai J, Liu Z, et al. Effect of antipsychotic medication alone vs combined with psychosocial intervention on outcomes of early-stage schizophrenia: A randomized, 1-year study. Arch Gen Psychiatry. 2010;67(9):895-904.  https://doi.org/10.1001/archgenpsychiatry.2010.105
  42. Kavanagh DJ. Recent developments in expressed emotion and schizophrenia. Br J Psychiatry. 1992;160:601-620.  https://doi.org/10.1192/bjp.160.5.601
  43. Subotnik KL, Casaus LR, Ventura J, et al. Long-Acting Injectable Risperidone for Relapse Prevention and Control of Breakthrough Symptoms After a Recent First Episode of Schizophrenia. A Randomized Clinical Trial. JAMA Psychiatry. 2015;72(8):822-829.  https://doi.org/10.1001/jamapsychiatry.2015.0270
  44. Kostyuk GP, Kourmyshev MV, Zaitseva MS, Kouzmenko AYu, Khannanova AN. Prolonged-release risperidone: analysis of 24-months treatment of patients with frequent hospitalizations. Social and Clinical Psychiatry. 2017;27(4):53-58. (In Russ.).
  45. Shmukler AB, Kostyuk GP, Sofronov AG. Local experience in paliperidone palmitate one-month formulation application in real-world setting. Social and Clinical Psychiatry. 2019;29(2):42-50. (In Russ.).
  46. Kane JM, Kishimoto T, Correll CU. Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies. World Psychiatry. 2013;12:216-226.  https://doi.org/10.1002/wps.20060
  47. Sorokin MY, Neznanov NG, Lutova NB, Wied VD. Revisiting Drug Compliance: The Need for a Holistic Approach in the Treatment of Severe Mental Disorders. Consortium Psychiatricum. 2021;2(3):17-25.  https://doi.org/10.17816/CP93
  48. McEvoy JP, Apperson LJ, Appelbaum PS, Ortlip P, Brecosky J, Hammill K. Insight in Schizophrenia. Its Relationship to Acute Psychopathology. Journal of Nervous and Mental Disorders. 1989;177:43-47. 
  49. Comparelli A, Savoja V, De Carolis A, Di Pietro S, Kotzalidis GD, Corigliano V, Falcone I, Tatarelli R, Ferracuti S, Girardi P. Relationships between psychopathological variables and insight in psychosis risk syndrome and first-episode and multiepisode schizophrenia. J Nerv Ment Dis. 2013;201(3):229-233.  https://doi.org/10.1097/NMD.0b013e3182834315
  50. Phahladira L, Asmal L, Kilian S, Chiliza B, Scheffler F, Luckhoff HK, du Plessis S, Emsley R. Changes in insight over the first 24 months of treatment in schizophrenia spectrum disorders. Schizophr Res. 2019;206:394-399.  https://doi.org/10.1016/j.schres.2018.10.013
  51. Mintz AR, Dobson KS, Romney DM. Insight in schizophrenia: a meta-analysis. Schizophr Res. 2003;61(1):75-88. 
  52. Lincoln TM, Lullman E, Rieff W. Correlates and long-term consequences of poor insight in patients with schizophrenia. A systematic review. Schizophr Bull. 2007;33(6):1324-1342.
  53. Amador XF, Flaum M, Andreasen NC, Strauss DH, Yale SA, Clark SC, Gorman JM. Awareness of illness in schizophrenia and schizoaffective and mood disorders. Arch Gen Psychiatry. 1994;51(10):826-836.  https://doi.org/10.1001/archpsyc.1994.03950100074007
  54. Schennach R, Meyer S, Seemüller F, Jäger M, Schmauss M, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkötter J, Heuser I, Maier W, Lemke MR, Rüther E, Klingberg S, Gastpar M, Möller HJ, Riedel M. Insight in schizophrenia-course and predictors during the acute treatment phase of patients suffering from a schizophrenia spectrum disorder. Eur Psychiatry. 2012;27(8):625-633.  https://doi.org/10.1016/j.eurpsy.2012.01.001
  55. McCormack M, Tierney K, Brennan D, Lawlor E, Clarke M. Lack of insight in psychosis: theoretical concepts and clinical aspects. Behav Cogn Psychother. 2014;42(3):327-338.  https://doi.org/10.1017/S1352465813000155
  56. Bajaj V, Sengupta S, Gupta DK. Psychopathology, insight and compliance in schizophrenia. Irish Journal of Psychological Medicine. Cambridge University Press. 2009;26(1):12-15. 
  57. Medina E, Salvà J, Ampudia R, Maurino J, Larumbe J. Short-term clinical stability and lack of insight are associated with a negative attitude towards antipsychotic treatment at discharge in patients with schizophrenia and bipolar disorder. Patient Pref Adher. 2012;66:23-629. 
  58. David A, Bedford N, Wiffen B, Gilleen J. Failures of metacognition and lack of insight in neuropsychiatric disorders. Philos Trans R Soc B. 2012;367:1379-1390. https://doi.org/10.1098/rstb.2012.0002
  59. Beck AT, Warman DM. Cognitive insight: theory and assessment. In: Amador X.F., David A.S., editors. Insight and psychosis: awareness of illness in schizophrenia and related disorders. 2. New York: Oxford University Press; 2004.
  60. Balzan RP. Overconfidence in psychosis: the foundation of delusional conviction? Cogent Psychol. 2016;3(1):1135855. https://doi.org/10.1080/23311908.2015.1135855
  61. Buchy L, Makowski C, Malla A, Joober R, Lepage M. A longitudinal study of cognitive insight and cortical thickness in first-episode psychosis. Schizophrenia Research. 2018;193:251-260.  https://doi.org/10.1016/j.schres.2017.06.048
  62. O’Connor JA, Ellett L, Ajnakina O, Schoeler T, Kollliakou A, Trotta A, Wiffen BD, Falcone AM, Di Forti M, Murray RM, Bhattacharyya S, David AS. Can cognitive insight predict symptom remission in a first episode psychosis cohort? BMC Psychiatry. 2017;17(1):54.  https://doi.org/10.1186/s12888-017-1210-9
  63. Dondé C, Laprévote V, Lavallé L, Haesebaert F, Fakra E, Brunelin J. Cognitive insight in individuals with an at‐risk mental state for psychosis: A meta‐analysis. Early Intervention in Psychiatry. 2021;15(3):449-456.  https://doi.org/10.1111/eip.12993
  64. de Vos AE, Pijnenborg GHM, Aleman A, van der Meer L. Implicit and explicit self-related processing in relation to insight in patients with schizophrenia. Cogn. Neuropsychiatry. 2015;20(4):311-329.  https://doi.org/10.1080/13546805.2015.1040151
  65. Van Camp L, Sabbe B, Oldenburg J. Cognitive insight: a systematic review. Clin Psychol Rev. 2017;55:12-24.  https://doi.org/10.1016/j.cpr.2017.04.011
  66. Sauvé G, Kline RB, Shah JL, Joober R, Malla A, Brodeur MB, Lepage M. Cognitive capacity similarly predicts insight into symptoms in first- and multiple-episode psychosis. Schizophrenia Research. 2019;(206):236-243.  https://doi.org/10.1016/j.schres.2018.11.013
  67. Braw Y, Sitman R, Sela T, Erez G, Bloch Y, Levkovitz Y. Comparison of insight among schizophrenia and bipolar disorder patients in remission of affective and positive symptoms: analysis and critique. Eur Psychiatry. 2012;27(8):612-618.  https://doi.org/10.1016/j.eurpsy.2011.02.002
  68. Raffard S, Bayard S, Gely-Nargeot MC, Capdevielle D, Maggi M, Barbotte E, Morris D, Boulenger JP. Insight and executive functioning in schizophrenia: a multidimensional approach. Psychiatry Res. 2009;167(3):239-250.  https://doi.org/10.1016/j.psychres.2008.04.018
  69. Wiffen BD, O’Connor JA, Russo M, Lopez-Morinigo JD, Ferraro L, Sideli L, Handley R, David AS. Are there specific neuropsychological deficits underlying poor insight in first episode psychosis? Schizophr Res. 2012;135(1-3):46-50.  https://doi.org/10.1016/j.schres.2011.11.017
  70. Quee PJ, van der Meer L, Bruggeman R, de Haan L, Krabbendam L, Cahn W, Mulder NC, Wiersma D, Aleman A. Insight in psychosis: relationship with neurocognition, social cognition and clinical symptoms depends on phase of illness. Schizophr Bull. 2011;37(1):29-37.  https://doi.org/10.1093/schbul/sbq133
  71. Asmal L, du Plessis S, Vink M, Chiliza B, Kilian S, Emsley R. Symptom attribution and frontal cortical thickness in first-episode schizophrenia. Early Interv Psychiatry. 2018;12(4):652-659.  https://doi.org/10.1111/eip.12358
  72. Boyer L, Aghababian V, Richieri R, Loundou A, Padovani R, Simeoni MC, Auquier P, Lançon C. Insight into illness, neurocognition and quality of life in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2012;36(2):271-276.  https://doi.org/10.1016/j.pnpbp.2011.10.008
  73. Bora E. Relationship between insight and theory of mind in schizophrenia: A meta-analysis. Schizophrenia Research. 2017;190:11-17.  https://doi.org/10.1016/j.schres.2017.03.029.
  74. Thirioux B, Harika-Germaneau G, Langbour N, Jaafari N. The Relation Between Empathy and Insight in Psychiatric Disorders: Phenomenological, Etiological, and Neuro-Functional Mechanisms. Front Psychiatry. 2020;10:966.  https://doi.org/10.3389/fpsyt.2019.00966
  75. Lysaker PH, Pattison ML, Leonhardt BL, Phelps S, Vohs JL. Insight in schizophrenia spectrum disorders: relationship with behavior, mood and perceived quality of life, underlying causes and emerging treatments. World Psychiatry. 2018;17(1):12-23.  https://doi.org/10.1002/wps.20508
  76. Liemburg EJ, van der Meer L, Swart M, Curcic-Blake B, Bruggeman R, Knegtering H, Aleman A. Reduced connectivity in the self-processing network of schizophrenia patients with poor insight. PLoS One. 2012;7(8):e42707. https://doi.org/10.1371/journal.pone.0042707
  77. Lysaker PH, Chernov N, Moiseeva T, Sozinova M, Dmitryeva N, Alyoshin V, Luther L, Karpenko O, Kostyuk G. Clinical insight, cognitive insight and metacognition in psychosis: Evidence of mediation. Journal of Psychiatric Research. 2021;140:1-6.  https://doi.org/10.1016/j.jpsychires.2021.05.030
  78. Lysaker PH, Vohs JL, Ballard R, et al. Metacognition, self-reflection and recovery in schizophrenia: review of the literature. Future Neurol. 2013;8(1):103-115. 
  79. Karpenko OA. Impact of psychoeducation on compliance of inpatients with first episode psychosis. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2020;120(6-2):92-98. (In Russ.). https://doi.org/10.17116/jnevro202012006292
  80. Pekkala E, Merinder L. Psychoeducation for schizophrenia. Cochrane Database Syst Rev. 2002;(2):CD002831. https://doi.org/10.1002/14651858.CD002831
  81. Xia J, Merinder LB, Belgamwar MR. Psychoeducation for schizophrenia. Cochrane Database of Systematic Reviews. 2011;(6):CD002831. https://doi.org/10.1002/14651858.CD002831.pub2
  82. Chan KW, Hui LM, Wong HY, Lee HM, Chang WC, Chen YH. Medication adherence, knowledge about psychosis, and insight among patients with a schizophrenia-spectrum disorder. J Nerv Ment Dis. 2014;202:25-29.  https://doi.org/10.1097/NMD.0000000000000068
  83. Quillams L, Addington J. Insight, knowledge, and beliefs about illness in first-episode psychosis. The Canadian Journal of Psychiatry/La Revue canadienne de psychiatrie. 2003;48:350. 
  84. Lincoln TM, Wilhelm K, Nestoriuc Y, Lincoln TM, Wilhelm K, Nestoriuc Y. Effectiveness of psychoeducation for relapse, symptoms, knowledge, adherence and functioning in psychotic disorders: a meta-analysis. Schizophr Res. 2007;96:232-245.  https://doi.org/10.1016/j.schres.2007.07.022
  85. Pijnenborg GH, van Donkersgoed RJ, David AS, Aleman A. Changes in insight during treatment for psychotic disorders: a meta-analysis. Schizophr Res. 2013;144(1-3):109-117.  https://doi.org/10.1016/j.schres.2012.11.018
  86. Dondé C, Senn M, Eche J, Kallel L, Saoud M, Brunelin J. Well-informed but not aware: The P.A.C.T. psychoeducation program for schizophrenia improves knowledge about, but not insight into, the illness. Asian J Psychiatr. 2019;46:15-18.  https://doi.org/10.1016/j.ajp.2019.09.034
  87. Henriksen MG, Parnas J. Self-disorders and schizophrenia: a phenomenological reappraisal of poor insight and noncompliance. Schizophr Bull. 2014;40(3):542-547.  https://doi.org/10.1093/schbul/sbt087
  88. Sharaf AY, Ossman LH, Lachine OA. A cross-sectional study of the relationships between illness insight, internalized stigma, and suicide risk in individuals with schizophrenia. Int J Nurs Stud. 2012;49(12):1512-1520. https://doi.org/10.1016/j.ijnurstu.2012.08.006
  89. Hawton K, Sutton L, Haw C, Sinclair J, Deeks JJ. Schizophrenia and suicide: systematic review of risk factors. Br J Psychiatry. 2005;187:9-20.  https://doi.org/10.1192/bjp.187.1.9
  90. Barrett EA, Mork E, Færden A, Nesvåg R, Agartz I, Andreassen OA, Melle I. The development of insight and its relationship with suicidality over one year follow-up in patients with first episode psychosis. Schizophr Res. 2015;162(1-3):97-102.  https://doi.org/10.1016/j.schres.2015.01.004
  91. Lopez-Morinigo JD, Di Forti M, Ajnakina O, Wiffen BD, Morgan K, Doody GA, Jones PB, Ayesa-Arriola R, Canal-Rivero M, Crespo-Facorro B, Murray RM, Dazzan P, Morgan C, Dutta R, David AS. Insight and risk of suicidal behaviour in two first-episode psychosis cohorts: Effects of previous suicide attempts and depression. Schizophr Res. 2019;204:80-89.  https://doi.org/10.1016/j.schres.2018.09.016
  92. Giusti L, Ussorio D, Tosone A, Di Venanzio C, Bianchini V, Necozione S, Casacchia M, Roncone R. Is personal recovery in schizophrenia predicted by low cognitive insight? Community Ment Health J. 2015;51(1):30-37.  https://doi.org/10.1007/s10597-014-9767-y
  93. Rossi A, Amore M, Galderisi S, Rocca P, Bertolino A, Aguglia E, Amodeo G, Bellomo A, Bucci P, Buzzanca A, Carpiniello B, Comparelli A, Dell’Osso L, di Giannantonio M, Mancini M, Marchesi C, Monteleone P, Montemagni C, Oldani L, Roncone R, Siracusano A, Stratta P, Tenconi E, Vignapiano A, Vita A, Zeppegno P, Maj M; Italian Network for Research on Psychoses. The complex relationship between self-reported ‘personal recovery’ and clinical recovery in schizophrenia. Schizophr Res. 2018;192:108-112.  https://doi.org/10.1016/j.schres.2017.04.040
  94. Beck EM, Cavelti M, Kvrgic S, Kleim B, Vauth R. Are we addressing the ‘right stuff’ to enhance adherence in schizophrenia? Understanding the role of insight and attitudes towards medication. Schizophr Res. 2011;132(1):42-49.  https://doi.org/10.1016/j.schres.2011.07.019
  95. De Las Cuevas C, de Leon J, Peñate W, Betancort M. Factors influencing adherence to psychopharmacological medications in psychiatric patients: a structural equation modeling approach. Patient Prefer Adherence. 2017;11:681-690.  https://doi.org/10.2147/PPA.S133513
  96. Cosh S, Zenter N, Ay ES, Loos S, Slade M, De Rosa C, Luciano M, Berecz R, Glaub T, Munk-Jørgensen P, Krogsgaard Bording M, Rössler W, Kawohl W, Puschner B. Clinical Decision Making and Mental Health Service Use Among Persons With Severe Mental Illness Across Europe. Psychiatric Services. 2017;68(9):970-974.  https://doi.org/10.1176/appi.ps.201600114
  97. Joosten EA, De Fuentes-Merillas L, de Weert GH, Sensky T, van der Staak CP, de Jong CA. Systematic review of the effects of shared decision-making on patient satisfaction, treatment adherence, and health status. Psychother Psychosom. 2008;77:219-226.  https://doi.org/10.1159/000126073
  98. Brom L, Hopmans W, Pasman HR, Timmermans DR, Widdershoven GA, Onwuteaka-Philipsen BD. Congruence between patients’ preferred and perceived participation in medical decision-making: a review of the literature. BMC Med Inform Decis Mak. 2014;14:25.  https://doi.org/10.1186/1472-6947-14-25
  99. Berketova TYu, Melnichenko GA, Bobrov AE, Kuligina MA, Samsonova LS, Rogozin AK, Chernogolov VA, Morgunova TB. Compliance with hormone replacement therapy in perimenopause (work experience of the educational program «Health of a woman older than 45 years»). Problems of Endocrinology. 2000;46(1):20-26. (In Russ.).
  100. Moore A, Sellwood W, Stirling J. Compliance and psychological reactance in schizophrenia. Br J Clin Psychol. 2000;39:287-295.  https://doi.org/10.1348/014466500163293.
  101. Morán-Sánchez I, Bernal-López MA, Pérez-Cárceles MD. Compulsory admissions and preferences in decision-making in patients with psychotic and bipolar disorders. Soc Psychiatry Psychiatr Epidemiol. 2020;55:571-580.  https://doi.org/10.1007/s00127-019-01809-4
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.